Zealand Pharma ends recruitment for phase III study of glepaglutide
![Photo: Zealand Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13563947.ece/ALTERNATES/schema-16_9/doc7iuz48ombsy1hxo7neaq.jpg)
All of the necessary patients have been found and recruited for a phase III study of glepaglutide, which is a potential treatment of short bowel syndrome (SBS), Zealand Pharma announces in a press release on Thursday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma enters USD 200m financing agreement
For subscribers
Zealand Pharma reports positive data from phase Ib trial
For subscribers